ArticleNature genetics2019
A genetics-led approach defines the drug target landscape of 30 immune-related traits.
Abstract read
In one paragraph
Article in Nature genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases.BMC medical genomics · 2022Pooled it
- Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes.Nature genetics · 2021Pooled it
- Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.Nature aging · 2021Trial
- Genome-scale perturbation signatures from primary human CD4bioRxiv : the preprint server for biology · 2026Article
- RIVER delivers multimodal gene-directed regulatory interactions across diverse biological contexts with broad application potentials.Science China. Life sciences · 2026Article
- Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?Journal of the Endocrine Society · 2026Review
- Human genetics across levels of biological organization.Nature reviews. Genetics · 2026Review
- Translating genome-wide association studies at multiple scales: Drug target prioritization, cellular architectures, and organ imaging.Cell genomics · 2026Review
- Network-based machine learning to identify biomarkers for systemic lupus erythematosus.BMC biology · 2026Article
- Personalized medicine as a novel therapeutic approach for autoimmune diseases: new insights and future prospects.Osong public health and research perspectives · 2026Article
- Comprehensive adjudication identifies 111 high-confidence loci for Alzheimer's disease and related dementias.medRxiv : the preprint server for health sciences · 2026Article
- Insulin-like growth factor binding protein-3 serves as a biomarker for resistance to enzalutamide in prostate cancer.Apoptosis : an international journal on programmed cell death · 2026Article
- Context-specific regulatory genetic variation in MTOR dampens neutrophil-T cell crosstalk in pneumonia-associated sepsis.Nature communications · 2026Article
- Network-based framework for studying etiology and phenotypic diversity in primary ciliopathies.Genome biology · 2026Article
- Combination antagonism of TNF superfamily signaling for T cell immunosuppression.Frontiers in immunology · 2026Article
- Genetic architecture of primary sclerosing cholangitis: shared pathways with inflammatory bowel disease and gut-liver axis mediation.International journal of surgery (London, England) · 2026Article
- Genomic analysis unlocks the potential of denosumab as a targeted therapy for Crohn's disease.Scientific reports · 2025Article
- A Co-essentiality Network of Cancer Driver Genes Better Prioritizes Anticancer Drugs.Genomics, proteomics & bioinformatics · 2025Article
- Mapping disease critical spatially variable gene programs by integrating spatial transcriptomics with human genetics.bioRxiv : the preprint server for biology · 2025Article
- A computational medicine framework integrating multi-omics, systems biology, and artificial neural networks for Alzheimer's disease therapeutic discovery.Acta pharmaceutica Sinica. B · 2025Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors.
Hai FangWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-3961-8572
ULTRA-DD Consortium
Hans De WolfJanssen Research & Development, Beerse, Belgium.
Bogdan KnezevicWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Katie L BurnhamWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-8680-2933
Julie OsgoodWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Anna SannitiWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Alicia Lledó LaraWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Silva KaselaEstonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.
Stephane De CescoAlzheimer's Research UK Oxford Drug Discovery Institute, Target Discovery Institute, University of Oxford, Oxford, UK.
Jörg K WegnerJanssen Research & Development, Beerse, Belgium.
Lahiru HandunnetthiWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Fiona E McCannKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Liye ChenBotnar Research Centre, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-1503-6017
Takuya SekineBotnar Research Centre, University of Oxford, Oxford, UK.
Paul E BrennanAlzheimer's Research UK Oxford Drug Discovery Institute, Target Discovery Institute, University of Oxford, Oxford, UK.
Brian D MarsdenKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-1937-4091
David DamerellStructural Genomics Consortium, University of Oxford, Oxford, UK.
Chris A O'CallaghanWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-9962-3248
Chas BountraStructural Genomics Consortium, University of Oxford, Oxford, UK.
Paul BownessBotnar Research Centre, University of Oxford, Oxford, UK.
Yvonne SundströmStructural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Lili MilaniEstonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.ORCID http://orcid.org/0000-0002-5323-3102
Louise BergStructural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Hinrich W GöhlmannJanssen Research & Development, Beerse, Belgium.ORCID http://orcid.org/0000-0002-6582-5455
Pieter J PeetersJanssen Research & Development, Beerse, Belgium.
Benjamin P FairfaxDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-7413-5002
Michael SundströmStructural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Julian C KnightWellcome Centre for Human Genetics, University of Oxford, Oxford, UK. julian@well.ox.ac.uk.ORCID http://orcid.org/0000-0002-0377-5536
Funding
Arthritis Research UK 20773European Research Council 281824Versus Arthritis 20773Wellcome Trust 090532Wellcome Trust 090532/Z/09/ZWellcome Trust 106169Wellcome Trust 106169/ZZ14/ZWellcome Trust 201488Wellcome Trust 201488/Z/16/ZWellcome Trust 203141Wellcome Trust 203141/Z/16/ZWellcome Trust 204969Wellcome Trust 204969/Z/16/Z
Abstract
Most candidate drugs currently fail later-stage clinical trials, largely due to poor prediction of efficacy on early target selection
Indexed as
Drug DiscoveryGene Regulatory NetworksGenome, HumanQuantitative Trait LociSelection, GeneticArthritis, RheumatoidGene Expression RegulationGenome-Wide Association StudyHumansImmunity, InnatePolymorphism, Single Nucleotide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.